A study of efficacy and safety of landiolol hydrochloride for pulmonary resection - A study of landiolol hydrochloride for pulmonary resection

ippon Medical School Hospital0 个研究点目标入组 64 人开始时间: 2017年10月1日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. supraventricular arrhythmia including atrial fibrillation or atrial flutter 2. patients with sick sinus syndrome including patients with pacemaker implantation 3. patients with severe heart failure (Class III or higher NYHA cardiac function classification) 4. patients with second or higher degree atrioventricular block 5. moderate to severe valve disease 6. patients who have experienced acute cardiovascular events, cerebrovascular events, infectious inflammation within the past 60 days 7. patients with tendency of bradycardia (resting heart rate under 55 times/min) 8. patients with systolic blood pressure less than 80 mmHg 9. patients who had been administered beta blockers before surgery 10. patients with severe bronchial asthma 11. patients who had typical honeycomb lung due to obstructive pulmonary disease (COPD stage 2 or higher) or diffuse lung disease (IP) 12. patients whose cause of atrial fibrillation was identified as electrolyte abnormality, WPW syndrome or hyperthyroidism and so on 13. patients who had been administered antiarrhythmic drugs except for digitalis before pulmonary surgery 14. patients in whom beta-blockers are contraindicated 15. chronic inflammatory diseases 16. patients with severe hepatic impairment 17. patients with severe renal impairment 18. others, patients who are judged inappropriate for this study by principle investigator

发起方

ippon Medical School Hospital